Otsuki Taiichiro Department
Hyogo Medical University(Specialty Division)
, Clinical Medicine Seminars
Hyogo Medical University(Specialty Division)
Thoracic Oncology, Clinical Medicine Seminars
Hyogo Medical University(Corporation/Other Facilities)
Cancer Center, Central Clinic
Position
■ Journal
1.
Original article
Serum HMGB1 as a diagnostic marker for malignant peritoneal mesothelioma. 2013/09
2.
Original article
[Environmental air pollutants and the risk of cancer]. 2013/11
3.
Original article
Biallelic germline and somatic mutations in malignant mesothelioma: Multiple mutations in transcription regulators including mSWI/SNF genes. 2015/02
4.
Original article
A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS(regimen, PS, histology or stage) index 2015/04
5.
Original article
Functional Alteration of Natural Killer Cells and Cytotoxic T Lymphocytes upon Asbestos Exposure and in Malignant Mesothelioma Patients 2015/06
6.
Original article
Epithelioid pleural mesothelioma concurrently associated with miliary pulmonary metastases and minimal change nephrotic syndrome - A hitherto undescribed case. 2015/09
7.
Case report
Consideration regarding immune checkpoint inhibitor-induced secondary adrenal insufficiency in patients lacking human leucocyte antigen-DR15 2021/01
AMP Converted from Intracelluarly transported adenosine upregulates p53 expression to induce malignant pleural mesothelioma cell apoptosis (Poster presentation,General Lecture) 2013/10/29
2.
A new prognostic index for overall survival in malignant pleural mesothelioma
-PHS index (Poster presentation,General Lecture) 2014/09/27
3.
Rare germline variants of transcription regulator genes in malignant mesothelioma (Poster presentation,General Lecture) 2014/09/27
4.
Clinical role of pleural effusion ADA levels in malignant pleural mesothelioma (Poster presentation,General Lecture) 2014/10/22
5.
Newly synthesized anticancer agent HUHS1015(naftopidil analogue) is effective for malignant pleural mesothelioma(MPM). (Poster presentation,General Lecture) 2014/10/22
6.
Postoperative chemotherapy after pleurectomy/decortication for malignant pleural mesothelioma (Poster presentation,General Lecture) 2014/10/22
7.
Immunohistochemistry as Prognostic Markers for Malignant Pleural Mesothelioma (Poster presentation,General Lecture) 2015/09/07
8.
Potent Anti-Mesothelioma Activity by the Novel Naftopidil Analogue HUHS1015,Preclinical Evidence for Treatment. (Oral presentation,General Lecture) 2015/09/08
9.
Naftopidil Is Effective in the Treatment of Malignant Pleural Mesothelioma. (Poster presentation,General Lecture) 2015/09/09
10.
NF2 mutations in malignant pleural mesothelioma synchronous with acoustic neuroma:disease-causing mutation or chance effect? (Oral presentation,General Lecture) 2015/09/09
11.
A report on three cases of intramuscular metastasis from malignant pleural mesothelioma (Poster presentation,General Lecture) 2015/12/20
12.
Examination of the serum soluble mesothelin-related peptide (SMRP) level in patients with malignant pleural mesothelioma (Poster presentation,General Lecture) 2016/05/02
13.
Patterns of Detectable Tumor Progression in Patients with Malignant Pleural Mesothelioma with an FDG-PET-Negative T1a Tumor (Poster presentation,General Lecture) 2016/05/02
14.
Relationship between Histological Type and Pleural Mesothelioma (Poster presentation,General Lecture) 2016/05/02
15.
Induction Chemotherapy Followed by Surgery for Malignant Pleural Mesothelioma (Poster presentation,General Lecture) 2016/05/03
16.
The Analysis of the Recurrence of the Patients Who Underwent Surgical Resection for Malignant Pleural Mesothelioma (Poster presentation,General Lecture) 2016/05/03
17.
PET/CT FOR PATIENTS WITH VERY EARLY CLINICAL STAGE OF MALIGNANT PLEURAL MESOTHELIOMA:WHEN CAT PET/CT DETECT TUMOR GROWTH OF TO/T1A MESOTHLIOMA? (Poster presentation,General Lecture) 2016/12/06
18.
between the stainability of the neurofibromatosis type 2 gene-related protein merlin and the tumor properties of mesotheliomas (Poster presentation,General Lecture) 2016/12/07
19.
Mesothelium Covering Pleural Plaque Is Not Primary Involved in Asbestos-Induced Mesothelial Carcinogenesis in Human (Poster presentation,General Lecture) 2016/12/07
20.
Cisplatin in Combination for Pemetrexed in the Treatment of Patients with Advanced Malignant Peritoneal Mesothelioma -Retrospective study of 24 cases (Poster presentation,General Lecture) 2016/12/16
21.
Two cases of pembrolizumab-induced secondary adrenal insufficiency (Web announcement,General Lecture) 2021/03/20